Sign In
Buy FLXN
$25.10
-0.0069 (-0.0275%)
At Close: Jun 22, 2026
Flexion Therapeutics: Sector Sell-Off Provides Opportunity To Reload At A Discount
05:27pm, Thursday, 22'nd Jul 2021
Flexion Therapeutics continues to report steady revenue growth as ZILRETTA moves deeper into commercialization. Despite the ongoing pandemic, Flexion reported encouraging Q1 earnings.
Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors
04:30pm, Monday, 12'th Jul 2021
BURLINGTON, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to it
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 02'nd Jul 2021
BURLINGTON, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 20,440 restricted stock units
4 Biotech and Life Sciences Stocks Trading Under $10 With Gigantic Upside Potential
06:15am, Saturday, 19'th Jun 2021
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
04:30pm, Monday, 14'th Jun 2021
BURLINGTON, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an
Flexion Therapeutics Announces Appointment of William T. Andrews, M.D.
04:15pm, Wednesday, 09'th Jun 2021
BURLINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that William T. Andrews, M.D., F.A.C.P., will join the company as Chief Medical Officer (C
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 04'th Jun 2021
BURLINGTON, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 8,510 restricted stock units.
New Strong Sell Stocks for June 4th
09:46am, Friday, 04'th Jun 2021
ASLN, BLRX, FLXN, ICMB, and MRNS have been added to the Zacks Rank #5 (Strong Sell) List on June 4, 2021.
Flexion Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference
04:30pm, Wednesday, 02'nd Jun 2021
BURLINGTON, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an
Flexion Therapeutics to Present at the RBC Capital Markets 2021 Virtual Global Healthcare Conference
04:30pm, Thursday, 13'th May 2021
BURLINGTON, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an a
Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q1 2021 Results - Earnings Call Transcript
08:25pm, Wednesday, 12'th May 2021
Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q1 2021 Results - Earnings Call Transcript
Flexion Therapeutics: Q1 Earnings Insights
05:05pm, Wednesday, 12'th May 2021
Shares of Flexion Therapeutics (NASDAQ:FLXN) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 40.00% year over year to ($0.57), which misse
Earnings Preview: Flexion Therapeutics
10:18am, Tuesday, 11'th May 2021
On Wednesday, May 12, Flexion Therapeutics (NASDAQ:FLXN) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 07'th May 2021
BURLINGTON, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to eight new employees consisting of 18,200 restricted stock units
Flexion Therapeutics to Report First-Quarter 2021 Financial Results on May 12, 2021
04:30pm, Wednesday, 05'th May 2021
BURLINGTON, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2021 financial results after the close of the U.S. fi
